Thus, these screening results indicated that PI3K pathway contributed the most to sustain the viability of HNSCC under palbociclib treatment, with PI3K inhibitors being identified as the most promising combination option. This evidence concerns the gene PIK3CA and head and neck squamous cell carcinoma.